Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3317207 | 0.84 | CASR (0.42) | CNR1CASR | |
| SCHEMBL3321099 | 0.84 | DPP4 (0.46) | CNR1OPRL1CNR2 | |
| SCHEMBL3317794 | 0.80 | CNR1 (0.46) | CNR1CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL8263707 | 0.78 | L3MBTL1 (0.49) | CNR1OPRL1 | |
| SCHEMBL3317456 | 0.75 | MCHR1 (0.39) | CNR1OPRM1OPRL1CACNA2D1CACNA1B | |
| SCHEMBL3317547 | 0.74 | HTR6 (0.45) | CNR1CNR2 | |
| SCHEMBL3319177 | 0.74 | SOS1 (0.37) | CNR1OPRL1CNR2 | |
| SCHEMBL3314526 | 0.73 | CACNA2D1 (0.43) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL3317174 | 0.72 | HRH4 (0.39) | CASR | |
| SCHEMBL3315251 | 0.72 | ACACB (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R&D) LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-1933830-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | Vernalis (R&D) Limited (GB) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007007057-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | VERNALIS (R & D) LIMITED (GB) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105651-A1 | ANTAGONISTS OF SNS SODIUM CHANNELS | CNR1, OPRL1, CHRNA10 | CNR1 1/4885OPRM1 16/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.